Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix with Itraconazole or Ritonavir in Prostate Cancer
NCT05679388Phase 1Terminated
- Sponsor
- University of Chicago
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of itraconazole and ritonavir in prostate cancer (PCa) (5 arms), sponsored by University of Chicago. Primary endpoint: Testosterone Suppression at 1 month. Started Feb 2023; status: terminated.
02
Drugs
itraconazoleritonavir
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05679388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679388.